C&L: Milano tapped to run ViroPharma

ViroPharma has named Vincent Milano to succeed Michel de Rosen as president and chief executive. De Rosen will continue as non-executive chairman. Also, Daniel Soland has been named COO.

NPS Pharmaceuticals President and CEO Tony Coles is moving to take the reins at Onyx Pharmaceuticals. Onyx CEO Hollings Renton had announced plans to retire last October. He steps out officially at the end of March. NPS COO Francois Nader, meanwhile, is stepping up to the Coles' position. Nader joined NPS in 2006 and was promoted to COO last year.

Richard Eno was named CEO of Metabolix.

ImmunoCellular Therapeutics announced that Manish Singh, Ph.D., MBA has been named president and CEO.

Akrimax Pharmaceuticals has named Alan Rubino as its new president.

Neuropharm Group has named Bob Prachar president US operations.

Dynavax announced that Dr. Martin Sanders has been appointed executive vice president and chief development officer.

Genta says that Richard Moran will retire as senior vice president and chief financial officer.

Proteolix has appointed Matthew Ferguson to the new position of chief financial officer.

Mylan announced the appointment of Eric Leeds as senior vice president and head of global investor relations.

Axial Biotech has named Eric K. Olson executive vice president of sales and marketing.

BioVascular has named Christopher Bussineau, Ph.D., vice president of pharmaceutical operations and Eric Karpinski vice president, business development and nonvascular operations.

Rigel Pharmaceuticals has named Daniel Magilavy, M.D. vice president of clinical research.

Ambrx has named Douglas Axelrod, M.D., Ph.D., as senior vice president for clinical research and development. 

t2cure has named Dr. Petra Rueck head of clinical operations.

Nile Therapeutics has named Hsiao Dee Lieu, M.D., F.A.C.C. as its vice president of clinical research.

GenomeQuest has hired Anthony Salerno as its new vice president of strategic business development.

Molecular Profiles has added Dr. Mike Fanfarillo as operations director and Dr. Robert Sherry as associate director in pharmaceutics.

Steven M. Agnoff has joined Inclinix in the position of vice president of marketing and product management.

BioStorage Technologies has named Dr. Wolfgang Hoffer as managing director of the company's European operations in Griesheim, Germany.

United BioSource Corporation has expanded its regulatory affairs group led by Mark Ammann, Pharm.D. and LaVonne Lang, Dr PH.

Ardea Biosciences has formed an inflammatory disease Scientific Advisory Board. They are: Mark Genovese, M.D.; John Sundy M.D., Ph.D.; Ikumi Tamai, Ph.D.

Aton Pharma announced that Dr. Fred Eshelman has joined the management board of Aton's parent company, Princeton Pharma Holdings.

ADVENTRX Pharmaceuticals announced that Eric Rowinsky, M.D. will join its board of directors.

Transgenomic has appointed David Pauluzzi to its board of directors.

Sucampo Pharmaceuticals announced that John Wright has been appointed to the board of directors.

Human Genome Sciences has appointed Maxine Gowen to its board of directors.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.